Lai Yu-Wei, Chung Ching-Hu
General Education Center, University of Taipei, Taipei 104, Taiwan.
Division of Urology, Taipei City Hospital Renai Branch, Taipei 106, Taiwan.
Clin Pract. 2024 Mar 28;14(2):570-578. doi: 10.3390/clinpract14020044.
Hepatocellular carcinoma (HCC) is a major contributor to the world's cancer burden. Understanding the HCC incidence rate in Taiwan is thus an interesting avenue of research.
From an NHI database, those patients who had been newly diagnosed with HCC and who had been listed on a registry in a catastrophic illness dataset during the years 2013-2021 were enrolled in this study. Antineoplastic agent usage and comorbidities were also studied.
The incidence rate of HCC decreased from 57.77 to 44.95 in 100,000 from 2013 to 2021. The average age of patients with HCC increased from 65.54 years old with a CCI score of 4.98 in 2013 to 67.92 years old with a CCI score of 5.49 in 2021. Among these HCC patients, the patients under antineoplastic agent treatment decreased from 53.47% to 31.41% from 2013 to 2021. The presence of comorbidities in HCC patients was about 55.77-83.01% with mild liver disease and 29.93-37.30% with diabetes (without complications) in the period 2013-2021.
The incidence rate of HCC slightly decreased in Taiwan. Due to antineoplastic agent usage decreasing over time, these results may indicate that more early-stage HCC patients detected in recent years were mainly treated with surgeries.
肝细胞癌（HCC）是全球癌症负担的主要构成因素。因此，了解台湾地区的HCC发病率是一个有趣的研究方向。
本研究纳入了2013年至2021年间在国民健康保险（NHI）数据库中首次被诊断为HCC且被列入重大伤病数据集登记册的患者。同时还研究了抗肿瘤药物的使用情况和合并症。
2013年至2021年期间，HCC发病率从每10万人中的57.77例降至44.95例。HCC患者的平均年龄从2013年的65.54岁（CCI评分为4.98）增加到2021年的67.92岁（CCI评分为5.49）。在这些HCC患者中，接受抗肿瘤药物治疗的患者比例从2013年的53.47%降至2021年的31.41%。2013年至2021年期间，HCC患者中合并轻度肝病的比例约为55.77%-83.01%，合并糖尿病（无并发症）的比例为29.93%-37.30%。
台湾地区HCC发病率略有下降。由于抗肿瘤药物的使用随时间减少，这些结果可能表明近年来检测出的更多早期HCC患者主要接受了手术治疗。
